Teicoplanin – therapeutic drug monitoring, AKI and...
Transcript of Teicoplanin – therapeutic drug monitoring, AKI and...
![Page 1: Teicoplanin – therapeutic drug monitoring, AKI and OPATopat-conference.com/wp-content/uploads/2018/06/... · Teicoplanin and nephrotoxicity • High threshold for dose reduction](https://reader033.fdocuments.in/reader033/viewer/2022060507/5f21dafa7525a768af49ccc6/html5/thumbnails/1.jpg)
LizCraigOPATPharmacistWythenshaweHospital
Teicoplanin–therapeuticdrugmonitoring,AKIandOPAT
![Page 2: Teicoplanin – therapeutic drug monitoring, AKI and OPATopat-conference.com/wp-content/uploads/2018/06/... · Teicoplanin and nephrotoxicity • High threshold for dose reduction](https://reader033.fdocuments.in/reader033/viewer/2022060507/5f21dafa7525a768af49ccc6/html5/thumbnails/2.jpg)
OPATservicesatWythenshawe• OPATserviceestablishedin2015
• Between500-700beddayspermonth
• Manageavarietyofinfections
• Multipleadministrationpathways
![Page 3: Teicoplanin – therapeutic drug monitoring, AKI and OPATopat-conference.com/wp-content/uploads/2018/06/... · Teicoplanin and nephrotoxicity • High threshold for dose reduction](https://reader033.fdocuments.in/reader033/viewer/2022060507/5f21dafa7525a768af49ccc6/html5/thumbnails/3.jpg)
TeicoplaninandOPAT
• Favourablekineticpropertiesallowoncedailyorthreetimesweeklydosing1,2
• Consideredasuitablealternativetovancomycin3,4
• UseincertainconditionsanindependentriskfactorforOPATfailure5
1.TarcogidSPC(Sanofi).LastupdatedontheeMC01/02/18.Accessedviawww.medicines.org.uk2.LamontE,SeatonRA,MacphersonMetal.Developmentofteicoplanindosageguidelinesforpatientstreatedwithinanoutpatientparenteralantibiotictherapy(OPAT)programme.JAntimicrobChemother2009;64:181–73.CavalcantiAB,GoncalvesAR,AlmeidaCS,BuganoDDG,SilvaE.Teicoplaninversusvancomycinforprovenorsuspectedinfection.CochraneDatabaseofSystematicReviews2010,Issue6.Art.No.:CD007022.4.SvetitskyS,etal.Comparativeefficacyandsafetyofvancomycinversusteicoplanin:systematicreviewandmeta-analysis.AntimicrobAgentsChemother2009;53:4069–79.5.ChristopherJ.A.Duncan,DavidA.Barr,AntoniaHo,EmmaSharp,LindsaySemple,R.AndrewSeaton.Riskfactorsforfailureofoutpatientparenteralantibiotictherapy(OPAT)ininfectiveendocarditis.JAntimicrobChemother.2013Jul;68(7):1650–1654
![Page 4: Teicoplanin – therapeutic drug monitoring, AKI and OPATopat-conference.com/wp-content/uploads/2018/06/... · Teicoplanin and nephrotoxicity • High threshold for dose reduction](https://reader033.fdocuments.in/reader033/viewer/2022060507/5f21dafa7525a768af49ccc6/html5/thumbnails/4.jpg)
Teicoplanin–therapeuticdosing
• Severe/deepseatedinfection–standarddosingsub-therapeutic1-3
• Dosesofupto12mg/kgrecommendedforinfectionsincludingosteomyelitisandendocarditis2,4
• Renallycleared–doseadjustmentrequiredinrenalimpairment1,4
• TDMrecommendedtoensuretargetlevelsattained
• Jul;68(7):1650–1654
1.WilsonAPR.Clinicalpharmacokineticsofteicoplanin.ClinPharmacokinet2000;39:167–832.MatthewsPC,etal.Teicoplaninlevelsinboneandjointinfections:arestandarddosessubtherapeutic?JInfect2007;55:408–133.GilbertDN,WoodCA,KimbroughRC.Failureoftreatmentwithteicoplaninat6milligrams/kilogram/dayinpatientswithStaphylococcusaureusintravascularinfection.TheInfectiousDiseasesConsortiumofOregon.AntimicrobialAgentsandChemotherapy.1991;35(1):79-87.4.TarcogidSPC(Sanofi).LastupdatedontheeMC01/02/18.Accessedviawww.medicines.org.uk
![Page 5: Teicoplanin – therapeutic drug monitoring, AKI and OPATopat-conference.com/wp-content/uploads/2018/06/... · Teicoplanin and nephrotoxicity • High threshold for dose reduction](https://reader033.fdocuments.in/reader033/viewer/2022060507/5f21dafa7525a768af49ccc6/html5/thumbnails/5.jpg)
Casestudy
• 70y/ofemaleadmittedtovascularwardatWythenshaweforAAArepair• ?mycoticaneurysm• Commencedonteicoplanin12mg/kgandceftriaxone2gdailyfor6weeksfollowingIDspecialistreview.
• DischargedtoOPATonday12• Stablerenalfunctionandlevels(range20-40mg/L)untilweek4oftreatment
• Week5;level>107mg/L.SubsequentlydevelopedAKIstage1
![Page 6: Teicoplanin – therapeutic drug monitoring, AKI and OPATopat-conference.com/wp-content/uploads/2018/06/... · Teicoplanin and nephrotoxicity • High threshold for dose reduction](https://reader033.fdocuments.in/reader033/viewer/2022060507/5f21dafa7525a768af49ccc6/html5/thumbnails/6.jpg)
CaseStudy
• 107mg/Lwasapeaklevel–althoughlevelsof>30persistedfor5daysaftercessation
• CalculatedGFRbelowthresholdfordoseadjustment;butpreviouslevelshadnotshownevidenceofaccumulation
• Delayinprocessingofteicoplaninlevel–dosesreceivedininterim• Riskfactors;co-prescriptionwithramipril,knownDM(dietcontrolled),?reactivationofmyeloma
![Page 7: Teicoplanin – therapeutic drug monitoring, AKI and OPATopat-conference.com/wp-content/uploads/2018/06/... · Teicoplanin and nephrotoxicity • High threshold for dose reduction](https://reader033.fdocuments.in/reader033/viewer/2022060507/5f21dafa7525a768af49ccc6/html5/thumbnails/7.jpg)
Teicoplaninreview
• Outcomesforpatientstreatedwithteicoplanininprevious12monthsexamined
• Usedin12patientsforvarietyofindications–alltreatedwith8-12mg/kg
• 3patientsdevelopedanAKI–allhadapriorassociatedlevel>60mg/L
AKI Patient characteristics: • Prolonged courses (4-6 weeks) • Deep seated infections • Co-morbidities (DM, post-transplant,
myeloma) • Nephrotoxic medications • Previously normal levels (ranging
20-40mg/L) and stable renal function
![Page 8: Teicoplanin – therapeutic drug monitoring, AKI and OPATopat-conference.com/wp-content/uploads/2018/06/... · Teicoplanin and nephrotoxicity • High threshold for dose reduction](https://reader033.fdocuments.in/reader033/viewer/2022060507/5f21dafa7525a768af49ccc6/html5/thumbnails/8.jpg)
Teicoplaninandnephrotoxicity
• Highthresholdfordosereductioninexistingrenalimpairment1
• 0.1%-1%incidenceofacutecreatininerise1
• IsolatedreportsofAKI2,3
• UseincardiacsurgicalprophylaxislinkedtoincreasedincidenceofAKI4
1.TarcogidSPC(Sanofi).LastupdatedontheeMC01/02/18.Accessedviawww.medicines.org.uk2.MHRADrugAnalysisPrints.Accessedviayellowcard.mhra.gov.uk/iDAP/3.Frye,R.F.,Job,M.L.andRosenbaum,B.J.(1992),TeicoplaninNephrotoxicity:FirstCaseReport.Pharmacotherapy:TheJournalofHumanPharmacologyandDrugTherapy,12:240-2424.OlssonDP,HolzmannMJ,SartipyU.Prophylaxisbyteicoplaninandriskofacutekidneyinjuryincardiacsurgery.JCardiothoracVascAnesth.2015;29(3):626-31
![Page 9: Teicoplanin – therapeutic drug monitoring, AKI and OPATopat-conference.com/wp-content/uploads/2018/06/... · Teicoplanin and nephrotoxicity • High threshold for dose reduction](https://reader033.fdocuments.in/reader033/viewer/2022060507/5f21dafa7525a768af49ccc6/html5/thumbnails/9.jpg)
TeicoplaninTDM
• TDMadvisedtoensureattainmentofminimumtherapeuticlevel1
• Noprovenlinkbetweenlevelandtoxicity–limitedevidencetosuggestTDMishelpfultoavoidtoxicity2
• Oftena“sendaway”testwithturnaroundofweeks
1. TarcogidSPC(Sanofi).LastupdatedontheeMC01/02/18.Accessedvia
www.medicines.org.uk2. More,etal.Nephrotoxicityofconcomitantuseoftacrolimusandteicoplanininallogeneic
hematopoieticstemcelltransplantrecipients.TransplantInfectiousDisease2014:16:329–332
![Page 10: Teicoplanin – therapeutic drug monitoring, AKI and OPATopat-conference.com/wp-content/uploads/2018/06/... · Teicoplanin and nephrotoxicity • High threshold for dose reduction](https://reader033.fdocuments.in/reader033/viewer/2022060507/5f21dafa7525a768af49ccc6/html5/thumbnails/10.jpg)
Lessonslearned
• ProlongeduseofhighdoseteicoplaninshouldbewithcautioninthosewithexistingriskfactorsforAKI
• Considerlonghalflifeandtimetosteadystatewheninterpreting
levels• Lowthresholdfordosereductioninrenalimpairment(GFR<80)• MinimumofweeklyU&EsandTDMifavailable,morefrequentlyif
higherriskpatient• Considerdosereductioniflevelstowardsupperendofdoserangeor
ifearlysignsofreducedrenalfunction
![Page 11: Teicoplanin – therapeutic drug monitoring, AKI and OPATopat-conference.com/wp-content/uploads/2018/06/... · Teicoplanin and nephrotoxicity • High threshold for dose reduction](https://reader033.fdocuments.in/reader033/viewer/2022060507/5f21dafa7525a768af49ccc6/html5/thumbnails/11.jpg)
Thankyouforlistening!